An observational study in Subjects After COVID-19 Vaccination, sponsored by Humanity & Health Medical Group Limited. Completed at 3 sites in 2 countries. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Humanity & Health Medical Group Limited · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in COVID-19 with a site in Japan — 10 open to participants now, 11 under way, 8 of them phase 3. COVID-19 · Japan.
Among the 75 studies in COVID-19 with a site in Japan, this one is the 12th largest by enrollment of the 15 observational ones that give a count, is one of 13 that started in 2022, is one of 15 observational ones, and was the 53rd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →10 of the 75 studies in COVID-19 with a site in Japan are open now. Recruiting first, the newest first:
Shionogi · Sites in Japan, United States, Bulgaria
Ages 12+
Shionogi · Sites in Japan
Ages 12–74
Pfizer · Sites in Japan, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Japan, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Japan, United States, Argentina and 21 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 5 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 19 · Phase 3 40 · Phase 4 1
First in 2016; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 379 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 602 across the 59 interventional studies, 3,346 across the 15 observational. Of the 58 that completed or were terminated, 36 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 75 have an industry lead sponsor. The 10 most frequent:
Humanity & Health Medical Group Limited is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Humanity & Health Medical Group Limited has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
5 of the studies in COVID-19 with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07746544Phase 3ShionogiStudy of Secutrelvir in Participants With COVID-19 | 2027-07-31 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07739446Chiba UniversityEffect of Surgical Masks in Preventing Acute Respiratory Infections | 2027-03 |
Add all 5 to your calendar (.ics) → With an account.
Among the 75 studies in COVID-19 with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is still raging across the world and vaccination is expected to lead us out of this pandemic. Although the efficacy of these vaccines is beyond doubt, safety still remains a concern. Liver injury, such as autoimmune hepatitis (AIH), has been reported after COVID-19 vaccination. The aim of this prospective study is to investigate the spectrum and profile of liver injury after COVID-19 vaccination in Asia-Pacific region and to explore the potential risk factors for the development of liver injury.
Subjects after COVID-19 vaccination
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who have received at lease one dose of approved COVID-19 vaccine
Biological: Approved COVID-19 vaccine
Vaccination for COVI9-19
Number of subjects with liver injury after COVID-19 vaccination
The COVID-19 vaccine-related liver injury (such as elevated liver enzymes, total bilirubin, etc.) was recorded and its spectrum and profile were evaluated.
Time frame: Within 24 weeks after COVID-19 vaccination
Ran from Sep 2022 to primary completion in Dec 2024, 27 months.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 27 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Humanity & Health Medical Group Limited